HealthDay, July 18
Dr. Caterina Minniti, director, Sickle Cell Center for Adults, and professor, Medicine, Einstein, explains the impact of a new medication for patients with sickle cell disease. This is the second treatment that has been FDA-approved for the disease in 20 years, and is detailed in an editorial Dr. Minniti authored for the New England Journal of Medicine.